Zacks Investment Research upgrades TFF Pharmaceuticals (NASDAQ:TFFP) to hold


TFF Pharmaceuticals (NASDAQ: TFFPGet a rating) has been upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report released on Tuesday, reports.

According to Zacks, “TFF Pharmaceuticals Inc. is an early-stage biopharmaceutical company. It focuses on the development and commercialization of inhalation products for the treatment of chronic respiratory diseases and lung conditions. TFF Pharmaceuticals Inc. is based in Austin, Texas. “

Separately, B. Riley cut his price target on TFF Pharmaceuticals stock from $24.00 to $18.00 and set a “buy” rating on the stock in a Tuesday, March 29 report.

Shares of NASDAQ: TFFP traded at $0.28 in midday trading on Tuesday, hitting $5.04. 1,184 shares of the company were traded, against an average volume of 118,982. TFF Pharmaceuticals has a 1-year low of $3.60 and a 1-year high of $12.28. The company has a market capitalization of $127.86 million, a price-earnings ratio of -4.03 and a beta of 2.14. The company’s 50-day simple moving average is $5.83 and its 200-day simple moving average is $6.71.

TFF Pharmaceuticals (NASDAQ: TFFPGet a rating) last released its quarterly results on Wednesday, May 11. The company reported ($0.33) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.05. TFF Pharmaceuticals had a negative net margin of 24,245.04% and a negative return on equity of 73.14%. In the same period a year earlier, the company posted ($0.33) earnings per share. On average, research analysts predict that TFF Pharmaceuticals will post -1.23 earnings per share for the current year.

In related news, director Aaron GL Fletcher purchased 542,000 shares of the company in a transaction that took place on Monday, April 4. The shares were purchased at an average cost of $6.47 per share, for a total transaction of $3,506,740.00. Following the purchase, the director now directly owns 100,000 shares of the company, valued at $647,000. The purchase was disclosed in a document filed with the Securities & Exchange Commission, accessible via this link. 9.90% of the shares are held by insiders of the company.

A number of large investors have recently changed their positions in the stock. Parallel Advisors LLC acquired a new position in TFF Pharmaceuticals in the fourth quarter worth $26,000. Newbridge Financial Services Group Inc. acquired a new position in TFF Pharmaceuticals in the fourth quarter worth $35,000. Marshall Wace LLP acquired a new position in TFF Pharmaceuticals in the third quarter worth $92,000. Goldman Sachs Group Inc. acquired a new position in TFF Pharmaceuticals in the fourth quarter worth $118,000. Finally, Stifel Financial Corp increased its stake in TFF Pharmaceuticals by 31.8% in the fourth quarter. Stifel Financial Corp now owns 14,500 shares of the company valued at $129,000 after purchasing an additional 3,500 shares during the period. Hedge funds and other institutional investors own 18.28% of the company’s shares.

TFF Pharmaceuticals Company Profile (Get a rating)

TFF Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, is focused on developing and commercializing pharmaceutical products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia. It intends to focus on the development of inhaled dry powder drugs for the treatment of lung diseases and conditions.

Featured articles

Get a Free Copy of Zacks Research Report on TFF Pharmaceuticals (TFFP)

For more information on Zacks Investment Research’s research offerings, visit

Get news and reviews for TFF Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for TFF Pharmaceuticals and related companies with’s free daily email newsletter.


Comments are closed.